Mr. Stuglik was appointed as a director and as a member of the Commercial Committee of Puma Biotechnology on July 5, 2020. He served as Chief Executive Officer of Verastem, Inc. from July 2019 through July 2023 and has served as a member of its Board of Directors since September 2017. He has also served as a member of the Board of Directors of Oncopeptides AB since May 2018.

Mr. Stuglik founded Proventus Health Solutions in January 2016 and has over three decades of experience in U.S. and international pharmaceutical development, product strategy, and commercialization. Prior to founding Proventus Health Solutions, Mr. Stuglik served as the Vice President and Chief Marketing Officer for the oncology division of Eli Lilly and Company, from 2009 to December 2015.

Mr. Stuglik received a Bachelor of Science in Pharmacy from Purdue University and holds memberships in the American Society of Clinical Oncology, the American Association of Cancer Research, and the International Association for the Study of Lung Cancer. Mr. Stuglik was selected as a director because of his significant experience and background in the life sciences industry and, in particular, commercialization of pharmaceutical therapies.